Degenerative neurological disorders

Flu might increase risk of Parkinson’s disease

Researchers observe a link between flu virus infection and Parkinson’s disease pathology, strengthening the case for flu vaccination and prompt antiviral treatment.…

What neuroscience pharmacist Viv Horton does for movement disorder and Parkinson’s services

As a neuroscience pharmacist, Viv Horton sees patients in a movement disorder clinic and Parkinson’s Advanced Symptom Unit, and delivers ward-based medicines optimisation services covering neurology, neurosurgery, neurorehabilitation and stroke services.…

What neuroscience pharmacist Viv Horton does for movement disorder and Parkinson’s services

As a neuroscience pharmacist, Viv Horton sees patients in a movement disorder clinic and Parkinson’s Advanced Symptom Unit, and delivers ward-based medicines optimisation services covering neurology, neurosurgery, neurorehabilitation and stroke services.…

Minocycline acne drug may offer new treatment for multiple sclerosis

The acne drug minocycline has been shown to slow the progress of relapsing-remitting multiple sclerosis in people experiencing their first symptoms of the condition, a study published in the New England Journal of Medicine has found.…

US sees rise in numbers of people dying from Alzheimer’s disease

Deaths from Alzheimer’s disease have risen by more than 50% in a 15-year period and are expected to increase further, a report from the US Centers for Disease Control and Prevention (CDC) is warning.…

A barrier to progress: getting drugs to the brain

Getting drugs across the blood-brain barrier could be key to developing more successful therapies to treat central nervous system disorders, such as Alzheimer’s disease, depression and epilepsy. Scientists are investigating a number of ways to achieve this, from using Trojan horses to smuggle …

A better way to manage Parkinson’s disease

Viv Horton explains how her hospital set up a Parkinson’s advanced symptom unit to provide holistic care for patients with Parkinson’s disease.…

EMA recommends first EU treatment for spinal muscular atrophy

The European Medicines Agency (EMA), which evaluates medicinal products for use in EU, has recommended nusinersen (Spinraza; Biogen) as a treatment for patients with spinal muscular atrophy (SMA). There is currently no approved therapy in the EU for SMA, a rare and often fatal genetic disease …

Randomised trial confirms efficacy of apomorphine for advanced Parkinson’s

A drug first produced in 1865 offers relief for people with advanced Parkinson’s disease, study confirms.…

FDA approves Austedo for Huntington’s chorea

The US Food and Drug Administration (FDA) has approved Austedo (deutetrabenazine) for the treatment of chorea associated with Huntington’s disease.…